Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization

Abstract

The majority of pathogenic mutations in the neurofibromatosis type I ( NF1 ) gene reduce total neurofibromin protein expression through premature truncation or microdeletion, but it is less well understood how loss-of-function missense variants drive NF1 disease. We have found that patient variants in codons 844 to 848, which correlate with a severe phenotype, cause protein instability and exert an additional dominant-negative action whereby wild-type neurofibromin also becomes destabilized through protein dimerization. We have used our neurofibromin cryogenic electron microscopy structure to predict and validate other patient variants that act through a similar mechanism. This provides a foundation for understanding genotype–phenotype correlations and has important implications for patient counseling, disease management, and therapeutics.

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 23, 2023
Source ID
10.1073/pnas.2208960120

Entities

People

  • Alan Merk
  • Alice Cheng
  • Dominic Esposito
  • Dwight V Nissley
  • Frank McCormick
  • Jana Ognjenovic
  • Joseph Darling
  • Lucy C. Young
  • Madeline R. Allison
  • Matt Drew
  • Matthew J. Sale
  • Reinhard Grisshammer
  • Ruby Goldstein De Salazar
  • Sae-Won Han
  • Vanessa Wall
  • Zi Yi Stephanie Huang

Organizations

  • Congressionally Directed Medical Research Programs
  • Frederick National Laboratory for Cancer Research
  • National Cancer Institute
  • National Institutes of Health
  • Seoul National University Hospital
  • University of California

Tags

Fields of Study

  • Biology

Readers

  • Breast cancer cell signaling and growth regulation.
  • Molecular and Cellular Biology
  • Molecular and genetic basis of cancer.

Technology Areas

  • Microelectronics